CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a research note issued to investors on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. SVB Leerink restated a market perform rating and set a $32.50 price target on shares of CymaBay Therapeutics in a research note on Tuesday, February 20th. Piper Sandler reiterated a neutral rating and issued a $32.50 target price (down previously from $33.00) on shares of CymaBay Therapeutics in a research note on Wednesday, February 14th. Raymond James lowered CymaBay Therapeutics from an outperform rating to a market perform rating and set a $32.50 target price for the company. in a research note on Tuesday, February 13th. BTIG Research reiterated a neutral rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 13th. Finally, UBS Group reiterated a neutral rating and issued a $32.50 target price (up previously from $25.00) on shares of CymaBay Therapeutics in a research note on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, CymaBay Therapeutics currently has an average rating of Hold and an average price target of $28.65.

CymaBay Therapeutics Trading Up 0.0 %

NASDAQ CBAY opened at $32.48 on Monday. The business’s 50-day moving average price is $29.45 and its 200 day moving average price is $22.22. CymaBay Therapeutics has a twelve month low of $7.26 and a twelve month high of $32.50. The company has a market capitalization of $3.73 billion, a PE ratio of -33.48 and a beta of 0.32.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.42 million. Equities analysts predict that CymaBay Therapeutics will post -1.38 EPS for the current year.

Insiders Place Their Bets

In related news, Director Janet Dorling sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $31.97, for a total value of $191,820.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Janet Dorling sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $31.97, for a total value of $191,820.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Charles Mcwherter sold 18,403 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $23.67, for a total value of $435,599.01. Following the completion of the sale, the insider now owns 15,000 shares in the company, valued at $355,050. The disclosure for this sale can be found here. Insiders have sold a total of 45,403 shares of company stock valued at $1,124,279 in the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Trading of CymaBay Therapeutics

Large investors have recently added to or reduced their stakes in the business. Harvest Fund Management Co. Ltd acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at approximately $26,000. Royal Bank of Canada increased its position in shares of CymaBay Therapeutics by 506.5% during the 3rd quarter. Royal Bank of Canada now owns 7,581 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 6,331 shares during the period. Jane Street Group LLC acquired a new position in shares of CymaBay Therapeutics during the 2nd quarter valued at $36,000. China Universal Asset Management Co. Ltd. increased its position in shares of CymaBay Therapeutics by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,516 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,238 shares during the period. Finally, Great West Life Assurance Co. Can acquired a new position in shares of CymaBay Therapeutics during the 1st quarter valued at $40,000. 95.03% of the stock is currently owned by institutional investors and hedge funds.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).